Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

OncLive’s August Roundup of Key FDA Approvals in Oncology

September 4th 2024

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

Dr Daver on the Potential Utility of Uproleselan in R/R AML

September 3rd 2024

Naval G. Daver, MD, discusses the potential utility of uproleselan in relapsed/refractory acute myeloid leukemia.

Blinatumomab May Be an Effective Alternative to Consolidation Chemotherapy in Down Syndrome B-ALL

September 3rd 2024

Sujith Samarasinghe, BSc, MBBS, MRCPCH, FRCPath, PhD, discusses the use of blinatumomab in children with Down syndrome acute lymphoblastic leukemia.

FDA Awards Fast Track Designation to CB-012 in Relapsed/Refractory AML

September 3rd 2024

The FDA has granted fast track designation to the allogeneic CAR T-cell therapy CB-012 for relapsed/refractory acute myeloid leukemia.

Dr Hantel on Eligibility Criteria Associated With Racial/Ethnic Disparities in Clinical Trial Enrollment in AML

August 29th 2024

Andrew Hantel, MD, discusses eligibility criteria associated with racial and ethnic disparities in clinical trial participation in acute myeloid leukemia.

Dr Daver on the Evolution of Survivorship and Treatment Outcomes in AML

August 29th 2024

Naval G. Daver, MD, discusses the evolution of survivorship in patients with acute myeloid leukemia.

The Future of AYA ALL

August 28th 2024

The panel concludes its discussion with a look at the future of AYA ALL treatment and the role of clinical trials and innovative therapies in improving outcomes for patients.

The Potential of Modified Treatment Regimens in AYA ALL

August 28th 2024

Experts on AYA ALL discuss the potential applicability of modified treatment regimens and the importance of multidisciplinary collaboration to meet the unique needs of patients.

Crovalimab Earns Approval in Europe for Paroxysmal Nocturnal Hemoglobinuria

August 27th 2024

The European Commission has approved crovalimab for adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.

Dr Daver on the Potential Role of MRD Assessment in AML Treatment

August 27th 2024

Naval G. Daver, MD, discusses the potential role of minimal residual disease assessments in acute myeloid leukemia.

Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma

August 26th 2024

Amitkumar Mehta, MD, discusses complexities and considerations around sequencing CAR T-cell therapies and bispecific antibodies in lymphoma.

Dr El-Jawahri on the Effects of Sexual Health Interventions in HSCT Recipients

August 26th 2024

Areej El-Jawahri, MD, discusses a trial investigating a multimodal intervention to enhance sexual function in patients who have previously received HSCT.

DSP-5336 Is Safe, Generates Responses in KMT2A+ or NPM1+ R/R AML

August 22nd 2024

Naval G. Daver, MD, discusses efficacy and safety data from the first-in-human phase 1/2 study investigating DSP-5336 for relapsed or refractory acute leukemia.

Dr Shouse on the Importance of NGS Testing in Follicular Lymphoma

August 22nd 2024

Geoffrey Shouse, DO, PhD, discusses the importance of performing next-generation sequencing in patients with follicular lymphoma.

CALBG 10403 in AYA ALL

August 21st 2024

A panel of experts discusses the use of CALBG 10403 in patients with AYA ALL, highlighting adverse events reported with the regimen and mitigation practices.

Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL

August 21st 2024

Michael Grunwald, MD, presents the case of a 32-year-old woman with AYA ALL, and Kelly Weaver, NP, DNP, discusses the role of cytogenetics in diagnosing patients with AYA ALL.

Dr Amanam on the Management of AEs Associated With JAK Inhibitors in Myelofibrosis

August 20th 2024

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.

Potentially Modifiable Eligibility Criteria Drive Enrollment Disparities in AML Clinical Trials

August 16th 2024

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

Dr Watts on the Final Results of the 2102-HEM-101 Trial in IDH1-Mutated AML

August 16th 2024

Justin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.

Dr Miller on the Use of NK Cell Therapy in Hematologic Malignancies

August 16th 2024

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.